Similar articles

• Everolimus and giant-cell astrocytomas in tuberous sclerosis.

  Jia J, Xiong L, Chen S. Jia J, et al. N Engl J Med. 2011 Feb 10;364(6):577. doi: 10.1056/NEJMc1013587. N Engl J Med. 2011. PMID: 21306252 No abstract available.
• Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.

  Franz DN. Franz DN. Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92. doi: 10.1586/era.11.93. Expert Rev Anticancer Ther. 2011. PMID: 21916571 Review.
• Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

  Józwiak S, Stein K, Kotulska K. Józwiak S, et al. Future Oncol. 2012 Dec;8(12):1515-23. doi: 10.2217/fon.12.146. Future Oncol. 2012. PMID: 23231513 Review.
• Everolimus and giant-cell astrocytomas in tuberous sclerosis.

  Nawashiro H, Shinomiya N. Nawashiro H, et al. N Engl J Med. 2011 Feb 10;364(6):576-7; author reply 577. doi: 10.1056/NEJMc1013587. N Engl J Med. 2011. PMID: 21306253 No abstract available.
• Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.

  Wheless JW, Klimo P Jr. Wheless JW, et al. J Child Neurol. 2014 Nov;29(11):1562-71. doi: 10.1177/0883073813501870. Epub 2013 Oct 7. J Child Neurol. 2014. PMID: 24105488 Review.